1. Ehrenkranz, J.R.L et al. Phlorizin: A Review. Diabetes Metab. Res. Rev. 2005, 21(1):31–8.doi: 10.1002/dmrr.532.
2. Chan, J.C.H, Chan, M.C.Y. SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug? Medicina 2023, 59, 388. https://doi.org/ 10.3390/medicina59020388
3. Gallo, L.A, Wright, E.M, Vallon, V. Probing SGLT2 as a Therapeutic Target for Diabetes: Basic Physiology and Consequences. Diabetes Vasc. Dis. Res. 2015, 12(2):78–89.doi: 10.1177/147916411992.
4. Lopaschuk, G.D, Verma, S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors. JACC Basic Transl. Sci. 2020, 5(6): 632–644.doi:10.1016/j.jacbts.2020.02.004.
5. Bailey C.J, Day C, Bellary S. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Curr. Diabetes Rep. 2022, 22(1):39–52. Doi:10.1007/s11892-021-01442-z.
6. Fonseca-Correa J I, Correa-Rotter R. Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Front. Med.2021, 8 777861.https://doi.org/10.3389/fmed.2021.777861.
7. Zinman B, Wanner C, Lachin J.M, Fitchett D, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med. 2015, 373(22): 2117–28. Doi:10.1056/NEJMoa1504720.
8. Rådholm K, Figtree G, Perkovic V, Solomon S.D, et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results from the CANVAS Program. Circulation 2018, 138(5): 458–468. Doi:10.1161/CIRCULATIONAHA.118.034222.
9. Neal B, Perkovic V, Matthews D.R et al. Rationale, Design and Baseline Characteristics of the Canagliflozin CardioVascular Assessment Study–Renal (CANVAS-R): A Randomized, Placebo-controlled Trial. Diabetes Obes. Metab. 2017, 19(3): 387–393.
10. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, et al. The Design and Rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial. Am. Heart J. 2018, 200, 83–89.doi: 10.1016/j.ahj.2018.01.012.
11. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2019, 380(4):347–357.doi: 10.1056/NEJMoa1812389.
12. Zelniker TA, Wiviott SD, Raz I, Im K, et al. SGLT2 Inhibitors for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials. Lancet 2019, 393(10166):31–39. Doi: 10.1016/S0140-6736(18)32590-X.
13. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N. Engl. J. Med. 2019, 381(21):1995–2008.doi: 10.1056/NEJMoa1911303.
14. Packer M, Anker SD, Butler J, Filippatos G, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N. Engl. J. Med. 2020, 383(15):1413–1424. Doi:10.1056/NEJMoa2022190.
15. Anker SD, Butler J, Filippatos G et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N. Engl. J. Med. 2021,385(16):1451–1461.doi:10.1056/NEJMoa2107038.
16. Bhatt DL, Szarek M, Steg PG, Cannon CP, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N. Engl. J. Med. 2020, 384(2): 117–128. Doi:10.1056/NEJMoa2030183.
17. Docherty KF, McMurray JJV. SOLOIST-WHF and Updated Meta-analysis: Sodium–Glucose Co-transporter 2 Inhibitors Should Be Initiated in Patients Hospitalized with Worsening Heart Failure. Eur. J. Heart Fail. 2021, 23(1):27–30. Doi:10.1002/ejhf.2075.
18. Voors AA, Angermann CE, Teerlink JR, Collins SP, et al. The SGLT2 Inhibitor Empagliflozin in Patients Hospitalized for Acute Heart Failure: A Multinational Randomized Trial. Nat. Med. 2022, 28(3):568–574. Doi:10.1038/s41591-021-01659-1.
19. Solomon SD, McMurray JJV, Claggett B, de Boer RA, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N. Engl. J.Med. 2022, 387: 1089–1098.doi: 10.1056/NEJMoa2206286.
20. Jhund PS, Kondo T, Butt JH, Docherty KF, et al. Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: A Patient-Level, Pooled Meta-Analysis of DAPA-HF and DELIVER. Nat. Med. 2022, 28(9):1956–1964.doi: 10.1038/s41591-022-01971-4.
21. Perkovic V, Jardine MJ, Neal B, Bompoint S, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N. Engl. J. Med. 2019, 380:2295–2306.doi: 10.1056NEJMoa1811744.
22. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2020, 383 (15):1436–1446.doi: 10.1056/NEJMoa2024816.
23. The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2022,388:117–127. Doi:10.1056/NEJMoa2204233.
24. Chen Li et al. The Efficacy and Safety of the Combination TherapyWith GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Front. Pharmacol. 2022, 13:838277.doi: 10.3389/fphar.2022.838277.
25. Ishan Hirji et al. Incidence of Urinary Tract Infection among Patients with Type 2 Diabetes in the UK General Practice Research Database (GPRD). J. Diabetes Complicat. 2012, 26(6): 513–6. Doi: 10.1016 /j.jdiacomp.2012.06.008.
26. Christoph Wanner et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N. Engl. J. Med. 2016, 375(4):323–334. Doi:10.1056/NEJMoa1515920.
27. Heerspink HJL, Cherney DZI. Clinical Implications of An Acute Dip in eGFR after SGLT2 Inhibitor initiation. Clin J Am Soc Nephrol.2021;16(8):1278-1280. Doi: 10.2215/CJN.02480221.
28. Type 2 Diabetes in Adults: Management; NCIE: London, UK, 2022; ISBN 978-1-4731-1477-7.
29. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes management Algorithm-2023 Update. Endocrine Practice, 2023;299(5):305-340. https://doi.org/10.1016/j.eparc.2023.02.001.
30. Pedoman Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Di Indonesia 2021. Perkumpulan Endokrinologi Indonesia. PB. PERKENI.2021
31. McDonald, M.; Virani, S.; Chan, M.; Ducharme, A.; Ezekowitz, J.A.; Giannetti, N.; Heckman, G.A.; Howlett, J.G.; Koshman, S.L.; Lepage, S.; et al. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure with Reduced Ejection Fraction. Can. J. Cardiol. 2021, 37(4):531–546. Doi: 10.1016/j.cjca.2021.01.017.
32. Heidenreich, P.A.; Bozkurt, B.; Aguilar, D.; Allen, L.A.; Byun, J.J.; Colvin, M.M.; Deswal, A.; Drazner, M.H.; Dunlay, S.M.; Evers, L.R.; et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022, 145, e895–e1032. https://doi.org/10.1161/CIR.0000000000001062
33. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022, 102, S1–S127.https://doi.org/10.1016/j.kint.2022.06.008